Inhaled corticosteroids in ventilated preterm neonates: a non-randomized dose-ranging study

BMC Pediatr. 2018 May 7;18(1):153. doi: 10.1186/s12887-018-1134-7.

Abstract

Background: Inhaled corticosteroids (ICS) offer targeted treatment for bronchopulmonary dysplasia (BPD) with minimal systemic effects compared to systemic steroids. However, dosing of ICS in the management of infants at high-risk of developing BPD is not well established. The objective of this study was to determine an effective dose of ICS for the treatment of ventilator-dependent infants to facilitate extubation or reduce fractional inspired oxygen concentration.

Methods: Forty-one infants born at < 32 weeks gestational age (GA) or < 1250 g who were ventilator-dependent at 10-28 days postnatal age were included. A non-randomized dose-ranging trial was performed using aerosolized inhaled beclomethasone with hydrofluoralkane propellant (HFA-BDP). Four dosing groups (200, 400, 600 and 800 μg twice daily for 1 week) with 11, 11, 10 and 9 infants in each group, respectively, were studied. The primary outcome was therapeutic efficacy (successful extubation or reduction in FiO2 of > 75% from baseline) in ≥60% of infants in the group. Oxygen requirements, complications and long-term neurodevelopmental outcomes were also assessed.

Results: The median age at enrollment was 22 (10-28) postnatal days. The primary outcome, therapeutic efficacy as defined above, was not achieved in any group. However, there was a significant reduction in post-treatment FiO2 at a dose of 800 μg bid. No obvious trends were seen in long-term neurodevelopmental outcomes.

Conclusions: Therapeutic efficacy was not achieved with all studied doses of ICS. A significant reduction in oxygen requirements was noted in ventilator-dependent preterm infants at 10-28 days of age when given 800 μg of HFA-BDP bid. Larger randomized trials of ICS are required to determine efficacy for the management of infants at high-risk for development of BPD.

Trial registration: This clinical trial was registered retrospectively on clinicaltrials.gov. The registration number is NCT03503994 .

Keywords: Bronchopulmonary dysplasia; Infant-newborn; Inhaled steroid; Metered dose inhaler; Preterm.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Bronchopulmonary Dysplasia / drug therapy*
  • Bronchopulmonary Dysplasia / therapy
  • Drug Administration Schedule
  • Drug Delivery Systems
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Respiration, Artificial
  • Treatment Outcome
  • Ventilator Weaning

Substances

  • Glucocorticoids

Associated data

  • ClinicalTrials.gov/NCT03503994